Enrollment completed for Moderna’s clinical study on bivalent anti-Covid booster adapted to Omicron BA.4 and BA.5 subvariants. The company announced it via Twitter: “We have recruited a total of 512 participants, in 21 centers – says Moderna – Enrollment in the Phase 2/3 clinical trial for the bivalent BA targeted vaccine booster candidate mRna-1273.222. 4 / BA.5, is complete “.
The US company had announced a few days ago that it had completed the request for authorization for the emergency use of this updated booster in the US – an application submitted to the FDA for a booster dose in over 18s – and in that context it had explained that the clinical study was in progress. As for the availability of the doses, Moderna had informed that he had re-measured the production of the new vaccine “to be ready, if authorized, to provide the doses in September”. The mRna platform, assured the CEO of Moderna, Stephan Bancel, “allows us to develop, study and deploy bivalent boosters that demonstrate superior protection against all tested variants, in record time”.
#Modern #vaccine #completed #enrollment #study #Omicron #booster